Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U3-1784 in Advanced Solid Tumours
NCT02690350Phase 1Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2016
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of u3-1784 in solid tumor (advanced stage) and hepatocellular carcinoma (HCC) (3 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of Patients with Adverse Events at 1 year and Number of Patients with Dose-Limiting Toxicities (DLTs) at 2 months. Started Feb 2016; status: terminated.
02
Drugs
u3-1784
03
Conditions
solid tumor (advanced stage)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02690350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690350.